Payment overview · 2025
General Payments
$2,826.81
158 reported records · 21 companies
Healthcare provider profile · identity verified
Brigetta Desiree Yancy, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARRERO, LA · NPI 1063475499
Verified facts
What the public records show
CMS Open Payments records show Brigetta Desiree Yancy, MD received $2,826.81 in general payments during 2025 across 158 reported records.
ABBVIE INC. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $692.70 | 24.5% | 45 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $412.70 | 14.6% | 25 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $279.16 | 9.9% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $181.14 | 6.4% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $153.85 | 5.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.93 | 5.1% | 7 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $144.66 | 5.1% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $142.23 | 5.0% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $120.67 | 4.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $112.58 | 4.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $73.52 | 2.6% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $71.98 | 2.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.92 | 2.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.71 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.15 | 1.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.19 | 1.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $24.88 | 0.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.23 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.89 | 0.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.79 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.93 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,826.81 | 158 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $342.83 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $331.69 | 29 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $300.91 | 19 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $256.98 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $232.66 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $217.81 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $181.14 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $153.85 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $149.91 | 11 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $144.66 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $142.23 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $131.36 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $120.67 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $112.58 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $86.83 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $86.83 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $86.83 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $73.52 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $71.98 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $71.33 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.25 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.30 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.71 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.67 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
139 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 378 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 334 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 68 |
| Gabapentin | Gabapentin | 254 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 47 |
| Losartan Potassium | Losartan Potassium | 204 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 202 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 55 |
| Famotidine | Famotidine | 160 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 28 |
| Linzess | Linaclotide | 143 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 27 |
| Trulicity | Dulaglutide | 139 | 24 |
| Buspirone Hcl | Buspirone Hcl | 138 | 19 |
| Ozempic | Semaglutide | 138 | 22 |
| Trazodone Hcl | Trazodone Hcl | 135 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 30 |
| Farxiga | Dapagliflozin Propanediol | 125 | 32 |
| Furosemide | Furosemide | 122 | 39 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 103 | 17 |
| Ibuprofen | Ibuprofen | 103 | 18 |
| Metformin Hcl | Metformin Hcl | 97 | 26 |
| Azithromycin | Azithromycin | 95 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 20 |
| Metformin Hcl Er | Metformin Hcl | 95 | 23 |
| Carvedilol | Carvedilol | 93 | 23 |
| Jardiance | Empagliflozin | 92 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 25 |
| Allopurinol | Allopurinol | 88 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 13 |
| Prednisone | Prednisone | 80 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 21 |
| Mounjaro | Tirzepatide | 75 | 17 |
| Eliquis | Apixaban | 74 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | suppressed |
| Potassium Chloride | Potassium Chloride | 69 | 17 |
| Azelastine Hcl | Azelastine Hcl | 66 | 31 |
| Lisinopril | Lisinopril | 66 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 16 |
| Baclofen | Baclofen | 54 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 11 |
| Omeprazole | Omeprazole | 52 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 49 | 11 |
| Clonidine Hcl | Clonidine Hcl | 47 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 42 | suppressed |
| Meloxicam | Meloxicam | 40 | 11 |
| Naproxen | Naproxen | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 37 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 12 |
| Promethazine Hcl | Promethazine Hcl | 33 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 16 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 14 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 20 |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Nystatin | Nystatin | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,826.81 · 158 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, FANAPT, GEMTESA, IBSRELA, INSPIRE, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYNDAQEL, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZTLido | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error